SynthesisJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.

Hao-Xiang Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.